ArticleHaematologica2020

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Anna Vidal-Crespo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.